5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
申请人:Semple Graeme
公开号:US20060167270A1
公开(公告)日:2006-07-27
The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R
2
is H, halogen, C
1-12
alkyl or C
1-12
haloalkyl; and R
3
is C
3-6
cycloalkyl, C
1-12
alkyl, C
1-12
haloalkyl, C
3-6
cycloalkyl-C
1-4
-alkylene, aryl-C
1-4
-alkylene or heteroaryl-C
1-4
-alkylene, wherein said aryl-C
1-4
-alkylene and heteroaryl-C
1-4
-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.
本发明涉及公式(Ia)的某些吡唑羧酸衍生物及其药学上可接受的盐,作为抗脂解作用剂和对RUP25受体的作用剂,其中:R2为H、卤素、C1-12烷基或C1-12卤代烷基;R3为C3-6环烷基、C1-12烷基、C1-12卤代烷基、C3-6环烷基-C1-4-烷基、芳基-C1-4-烷基或杂环芳基-C1-4-烷基,其中所述的芳基-C1-4-烷基和杂环芳基-C1-4-烷基可以选择性地被1至5个在权利要求书中列出的取代基所取代。本发明还提供了含有该化合物的药物组合物,并且提供了使用该化合物和该组合物治疗代谢相关疾病的方法,包括血脂异常、动脉粥样硬化、冠心病、胰岛素抵抗、2型糖尿病、X综合症等。此外,本发明还提供了与其他活性剂组合的药物组合物,例如属于α-葡萄糖苷酶抑制剂、醛还原酶抑制剂、双胍类、HMG-CoA还原酶抑制剂、角鲨烷合成抑制剂、纤维酸类、LDL降解增强剂、血管紧张素转换酶(ACE)抑制剂、胰岛素分泌增强剂、噻唑烷二酮等类别的活性剂。